ESTRO 2023 - Abstract Book

S1198

Digital Posters

ESTRO 2023

Conclusion Cardiac and coronary assessment in prostate cancer patients treated with ADT is a relevant strategy leading to therapeutic intervention in half of the patients. Nevertheless, it is necessary to develop prospective tools to better select patients who will benefit from this CW.

PO-1479 Management of androgen deprivation therapy (ADT) by French radiation oncologists, TALISMAN study

G. Crehange 1 , T. Lebret 2 , A. Thiery-Vuillemin 3 , N. Pello-Leprince-Ringuet 4 , V. Perrot 4 , J. Rigaud 5

1 Institut curie, Radiation Oncology, Paris, France; 2 Hôpital Foch , Urology, Suresnes, France; 3 University Hospital Jean Minjoz, Medical Oncology, Besançon, France; 4 IPSEN Pharma, Research, Boulogne Billancourt, France; 5 CHU Hôtel Dieu, Urology, Nantes, France Purpose or Objective Modalities of use of ADT, like triptorelin, have evolved this last decade, following results of intensification trials and their implementation in guidelines. Our purpose here was to describe management of ADT by radiation oncologists (RadOnc) in real life, including planned total duration of ADT and concomitant treatments. Materials and Methods Initiated in 2020, a prospective, multicenter, non-interventional study is ongoing in France (TALISMAN, NCT04593420). Patients with histologically confirmed prostate cancer (PCa), eligible for ≥ 12-month triptorelin therapy within its label were enrolled. Interim analysis of baseline data was planned when 50% of 786 patients were enrolled. A descriptive analysis of baseline parameters of subgroups according to the specialty of investigator was performed. Results 509 patients were included in the interim analysis; 56.8% were included by urologists, 40.1% (n = 204) by RadOnc and 3.1% by medical oncologists. Main baseline parameters by specialty of investigator are presented in Table. Among patients included by RadOnc, 3/4 received concomitant PCa treatment (77.8%), mostly external radiotherapy on prostate area (61.6%) and/or nodal area (26.5%). At least one visit to another physician was planned for 56.1% of patients, main one being the cardiologist (29.6%). Conclusion 48.3% of patients included by RadOnc were at high risk localized PCa stage, and 43.1% were planned to 24-36 months total triptorelin treatment, main reasons of choice of duration of treatment being Gleason score, PSA level and guidelines. Tumor aggressiveness parameters adapted to PCa stages seem to be the main drivers of choice of planned total duration of ADT. Evaluation of cardiovascular risk by the cardiologist was part of the standard management of ADT by RadOnc.

PO-1480 Time to testosterone recovery following long-course LHRH agonists and prostate cancer outcomes

K. Webb 1,2 , J. Murray 1 , A. Reid 1 , A. Sottoriva 2 , D. Dearnaley 1

1 Royal Marsden Hospital, Academic Urology Unit, Sutton, United Kingdom; 2 Institute of Cancer Research, Centre for Evolution and Cancer, Sutton, United Kingdom Purpose or Objective Time to testosterone recovery following cessation of long-course luteinizing hormone-releasing hormone (LHRH) agonists in prostate cancer (PCa) varies significantly between patients. Absent or delayed recovery may have a detrimental impact on physical and mental health. However, it has been suggested that it may be related to improved PCa outcomes, analogous